Erratum to: Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma

Affiliations

¹ Department of Urology, Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan.
² Department of Urology, Nippon Medical School Hospital, Tokyo, Japan.
³ Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan.
⁴ Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
⁵ Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
⁶ Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan.
⁷ Bristol-Myers Squibb, Tokyo, Japan.
⁸ Ono Pharmaceutical Co., Ltd., Osaka, Japan.
⁹ Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Published Erratum

Yoshihiko Tomita et al. Jpn J Clin Oncol. 2021.

. 2021 Dec 1;51(12):1770.

doi: 10.1093/jjco/hyab161.

¹ Department of Urology, Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan.
² Department of Urology, Nippon Medical School Hospital, Tokyo, Japan.
³ Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan.
⁴ Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
⁵ Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
⁶ Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan.
⁷ Bristol-Myers Squibb, Tokyo, Japan.
⁸ Ono Pharmaceutical Co., Ltd., Osaka, Japan.
⁹ Department of Urology, Keio University School of Medicine, Tokyo, Japan.

No abstract available

Erratum for

Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.
Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kaneko H, Tajima Y, Oya M. Tomita Y, et al. Jpn J Clin Oncol. 2021 Nov 1;51(11):1656-1664. doi: 10.1093/jjco/hyab114. Jpn J Clin Oncol. 2021. PMID: 34350454 Free PMC article.